Work

A Tumor-Localized Approach to Bypass Anti-4-1BB Immuno-Toxicity

Year: 2019

Type: article

Abstract: 4-1BB (CD137) is an important costimulatory molecule upregulated on antigen-experienced T cells, however, clinical development of 4-1BB agonists has stalled because of significant liver immuno-toxicity. Using rational protein engineering, a next-generation anticalin-antibody–based therapy achieved localized 4-1BB activation triggered by tumor-expressed antigen, helping to revitalize this pathway in immuno-oncology. See related article by Hinner et al., p. 5878

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-19-1799

Authors: Tina Tianjiao Su, Xiaobin Gao, Jun Wang

Institution: Yale University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Bristol-Myers Squibb